Congenital dyserythropoietic anemia, often called CDA, is a rare inherited blood disorder. In this disease, the bone marrow makes red blood cells in an abnormal way. Many young red blood cells do not grow and mature normally. Because of this, the body ends up with too few healthy red blood cells, and anemia happens. The word “congenital” means a person is born with it, and “dyserythropoietic” means red blood cell production is abnormal. CDA is not one single disease. It is a group of related genetic disorders with similar blood problems but different types and genes. [Orphanet]
Congenital dyserythropoietic anemia, usually called CDA, is a rare inherited blood disorder. In this disease, the bone marrow makes red blood cells in an abnormal way, so many young red blood cells die too early before they become healthy mature cells. That causes chronic anemia, tiredness, jaundice, enlarged spleen, gallstones, and sometimes iron overload even in people who do not receive many transfusions. CDA is not one single illness; it is a group of disorders, and treatment often depends on the subtype, especially CDA type I, where interferon can help some patients. [1]
In simple words, CDA means the body is trying to make red blood cells, but the process is faulty. The bone marrow may look very active, yet many red blood cell precursors die too early or develop in an unusual shape. This is called ineffective erythropoiesis. Some people have mild disease, while others have severe anemia, jaundice, enlarged spleen, gallstones, iron overload, or need blood transfusions. Some types are found in infancy, while milder forms may be diagnosed later in childhood or even adulthood. [GeneReviews]
CDA is also known by several related names. The most common short name is CDA. Some doctors may say congenital dyserythropoietic anaemia using British spelling. Type II CDA is also linked with the older name HEMPAS, which means hereditary erythroblastic multinuclearity with a positive acidified serum test. These names refer to the same family of disorders, but the exact name depends on the subtype. [Orphanet]
Types
- CDA Type I is one of the classic forms. It is usually inherited in an autosomal recessive way. Many patients have moderate to severe anemia, jaundice, and an enlarged spleen. Some babies can have problems before birth, and some patients develop iron overload over time. The main genes linked to this type are CDAN1 and C15orf41, which is also called CDIN1. [GeneReviews]
- CDA Type II is the most common classic type. It is also usually autosomal recessive. It often causes mild to severe anemia, jaundice, enlarged liver or spleen, gallstones, and later iron overload. It is mainly caused by disease-causing changes in the SEC23B gene. Type II is the one most strongly linked with the old name HEMPAS. [GARD]
- CDA Type III is a very rare type. It is known for very large multinucleated erythroblasts in the bone marrow. Some cases are mild, but severity can vary. Classical CDA III has been linked to KIF23, and more recent work has also linked some recessive CDA III cases to RACGAP1. [Orphanet]
- CDA Type IV is a rare type linked to KLF1 changes. It is often described as autosomal dominant and can cause severe anemia, abnormal red cell development, and other red cell changes. [Orphanet]
- X-linked thrombocytopenia with congenital dyserythropoietic anemia is another rare related form. It is linked to GATA1 mutations. In this form, the person can have both abnormal red blood cell production and low platelets, so bleeding problems may also happen. [Orphanet]
- Other rare and syndromic CDA-like forms have also been described. Research reviews report additional genes such as ALAS2, VPS4A, and rare newer variants affecting red cell division and maturation. This means CDA is now understood as a growing group of inherited disorders, not only the original three classic types. [Review]
Causes
Because CDA is a genetic disorder, its “causes” are usually inherited gene changes, not food, infection, or lifestyle. Many patients are born with a harmful change in a gene that controls how red blood cells grow, divide, mature, or handle cell structure inside the bone marrow. [Orphanet]
- CDAN1 gene mutation can cause CDA type I. This gene makes codanin-1. When it does not work normally, red cell development becomes faulty. [GeneReviews]
- C15orf41 / CDIN1 gene mutation can also cause CDA type I. This gene works closely with codanin-1, so defects in it can disturb red blood cell maturation. [Review]
- SEC23B gene mutation is the main cause of CDA type II. This gene helps move proteins inside the cell. When it is abnormal, erythroblasts develop in an unusual way. [GARD]
- KIF23 gene mutation can cause some cases of CDA type III. This gene is involved in cell division, so faulty cell division can produce abnormal multinucleated erythroblasts. [Review]
- RACGAP1 gene mutation is another rare cause of CDA type III. It affects the centralspindlin complex, which is important during cell division. [Review]
- KLF1 gene mutation causes CDA type IV in some patients. KLF1 is an erythroid transcription factor, meaning it helps turn important red cell genes on and off. [Review]
- GATA1 gene mutation can cause an X-linked CDA form with thrombocytopenia. This affects both red blood cell production and platelet development. [Review]
- ALAS2 gene mutation has been reported in an X-linked dominant CDA-like form, especially in females. This gene is involved in heme production. [Review]
- VPS4A gene mutation can cause a syndromic CDA-related disorder with anemia and dyserythropoiesis in some patients. [Review]
- Autosomal recessive inheritance is a major cause pattern in CDA I and CDA II. This means a child inherits one faulty gene copy from each parent. [Orphanet]
- Autosomal dominant inheritance is a cause pattern in some rare CDA forms, such as some KLF1-related cases. Only one faulty copy may be enough to cause disease. [Orphanet]
- X-linked inheritance causes some rare CDA forms, especially those related to GATA1 and some ALAS2-associated disease. [Review]
- De novo mutation, meaning a new gene change that was not inherited from either parent, can happen in some rare syndromic cases such as VPS4A-related disease. [Review]
- Defective erythroblast maturation is a direct disease-causing mechanism in CDA. The young red cells do not mature into normal adult red cells. [Orphanet]
- Abnormal cell division is another cause mechanism. Some CDA genes disturb the way erythroblasts split, leading to binucleated or multinucleated cells. [Review]
- Abnormal chromatin structure is important in CDA I. The nucleus of the erythroblast may look unusual, and this is part of the disease mechanism. [GeneReviews]
- Abnormal protein trafficking inside the cell is a cause mechanism in CDA II because SEC23B helps move proteins through the COPII pathway. [Review]
- Ineffective erythropoiesis itself is a core cause of anemia in CDA. The bone marrow makes many precursors, but many die early or remain abnormal. [Orphanet]
- Hemolysis, or increased breakdown of red blood cells, adds to the anemia in many CDA patients. So the disease is often caused by both poor production and shortened red cell survival. [Review]
- Unknown rare genes are likely responsible in some patients who look like they have CDA but do not yet have a known genetic diagnosis. Reviews note that new CDA genes continue to be discovered. [Review]
Symptoms
- Tiredness is one of the most common symptoms because anemia means less oxygen reaches the body tissues. [MedGen]
- Weakness can happen for the same reason. People may feel less energy during normal activity. [MedGen]
- Pale skin can appear because there are fewer healthy red blood cells and less hemoglobin. [GARD]
- Jaundice, which means yellow skin or yellow eyes, is common because abnormal red blood cells break down and raise bilirubin. [GARD]
- Enlarged spleen can happen in many patients, especially in CDA I and CDA II. [GeneReviews]
- Enlarged liver may also be seen, especially in some children and in people with iron overload or chronic hemolysis. [GARD]
- Gallstones may develop because long-term breakdown of red blood cells increases bilirubin in bile. [GARD]
- Shortness of breath can happen when anemia becomes more severe and the body cannot carry enough oxygen. [MedGen]
- Fast heartbeat may happen because the heart tries to move more oxygen around the body when hemoglobin is low. [MedGen]
- Poor growth or delayed growth can happen in some children with more severe disease. [Review]
- Dark urine can happen in some patients when red blood cells break down more than usual. [Review]
- Iron overload symptoms may appear later, such as tiredness, abdominal discomfort, liver problems, or organ damage, because CDA can increase iron absorption even without many transfusions. [GeneReviews]
- Symptoms before birth or at birth can happen in severe cases, including fetal anemia, jaundice in the newborn period, or very serious illness before birth. [GeneReviews]
- Bleeding tendency can happen in the GATA1-related form because platelets may also be low. [Review]
- Bone marrow-related chronic anemia symptoms such as dizziness, reduced exercise tolerance, and general poor stamina may be present in patients with ongoing anemia. [Orphanet]
Diagnostic tests
CDA diagnosis usually needs a combination of history, physical examination, blood tests, bone marrow study, and genetic testing. One single test is usually not enough. The exact test plan depends on the patient’s age, symptoms, anemia severity, and suspected subtype. [Orphanet]
- General physical examination helps the doctor look for pallor, jaundice, poor growth, and other visible signs of chronic anemia. [Orphanet]
- Skin and eye inspection for jaundice helps show bilirubin buildup from red cell breakdown. [GARD]
- Palpation of the spleen means the doctor gently feels the abdomen to check if the spleen is enlarged. [GeneReviews]
- Palpation of the liver helps check for hepatomegaly, which may be present in some patients. [GARD]
- Growth and developmental assessment is useful in children because some forms can affect growth and early health. [GeneReviews]
- Detailed family history is a practical manual clinical assessment. It helps doctors see whether similar anemia, jaundice, gallstones, or transfusion needs are present in relatives. [Orphanet]
- Pedigree review means mapping affected family members to see whether the pattern looks autosomal recessive, autosomal dominant, or X-linked. [Review]
- Complete blood count (CBC) is a key lab test. It shows hemoglobin level and red blood cell indices and confirms anemia. [Orphanet]
- Reticulocyte count helps show how strongly the marrow is responding. In CDA, the reticulocyte rise may be less than expected for the degree of anemia because erythropoiesis is ineffective. [Review]
- Peripheral blood smear lets the laboratory look at red blood cell shape, size, and abnormal immature cells in the blood. [Orphanet]
- Bilirubin level, especially indirect bilirubin, helps detect hemolysis and explains jaundice in many patients. [Review]
- Lactate dehydrogenase (LDH) is often increased when red blood cells are breaking down. [Review]
- Haptoglobin may be low when hemolysis is present, so it supports the diagnosis picture. [Review]
- Iron studies, including serum iron and transferrin saturation, help detect iron overload or abnormal iron handling. [GeneReviews]
- Serum ferritin is commonly used to follow body iron burden, especially in patients with transfusions or increased absorption. [GeneReviews]
- Bone marrow aspirate is one of the most important tests. It can show abnormal erythroblasts, binucleated cells, multinucleation, and other dysplastic red cell precursors. [Orphanet]
- Bone marrow biopsy may be done together with the aspirate to study marrow architecture and erythroid hyperplasia in more detail. [Orphanet]
- Electron microscopy of marrow erythroblasts can be very helpful in selected cases, especially for classic ultrastructural patterns such as the “Swiss cheese” chromatin appearance in CDA I. [Review]
- Genetic testing is now a major diagnostic test. Panels or sequencing can confirm mutations in genes such as CDAN1, CDIN1, SEC23B, KIF23, KLF1, GATA1, RACGAP1, or VPS4A. [Review]
- Imaging tests, especially abdominal ultrasound for liver, spleen, and gallstones, and MRI for iron overload in organs, are important supportive tests after diagnosis or during follow-up. They do not prove CDA alone, but they help measure complications. [GARD]
Congenital dyserythropoietic anemia is a rare inherited disorder of red blood cell production. The body cannot make normal red blood cells in the usual way, so anemia happens. The major forms are CDA I, II, III, and IV, with other rare X-linked and syndromic forms also known. The most important causes are gene mutations, not lifestyle factors. Common problems include tiredness, weakness, pale skin, jaundice, enlarged spleen, gallstones, and iron overload. The most important tests are CBC, reticulocyte count, blood smear, bilirubin and iron tests, bone marrow study, and genetic testing. [Orphanet]
Non-pharmacological treatments and supportive therapies
1. Regular hematology follow-up means seeing a blood specialist again and again over time. This helps track hemoglobin, reticulocytes, bilirubin, ferritin, liver iron, spleen size, growth in children, and long-term complications. The purpose is early detection of worsening anemia, iron overload, bone disease, and organ damage. The mechanism is simple: close follow-up allows treatment changes before complications become severe. [3]
2. Genetic confirmation of the CDA subtype is very important because treatment response can differ by subtype. The purpose is to avoid confusion with thalassemia, myelodysplasia, or other inherited anemias. The mechanism is that molecular diagnosis helps doctors choose the right monitoring plan and recognize cases where interferon alfa may work, especially in CDA type I. [4]
3. Red blood cell transfusion support is used when anemia is severe or causing symptoms. The purpose is to raise hemoglobin, improve oxygen delivery, reduce extreme fatigue, and help growth and development in children. The mechanism is direct replacement of missing red blood cells. Reviews of CDA management describe transfusion support as a standard part of care when hemoglobin falls very low or symptoms become important. [5]
4. Iron overload surveillance is one of the most important parts of CDA care. The purpose is to detect excess iron before it damages the liver, heart, or endocrine organs. The mechanism is regular checking with ferritin and, when needed, MRI-based liver iron or organ iron assessment. CDA can cause iron loading even without many transfusions because ineffective erythropoiesis increases iron absorption. [6]
5. MRI-based liver iron measurement is a useful noninvasive tool. The purpose is to see how much iron is already stored in the body. The mechanism is imaging that estimates tissue iron burden better than symptoms alone. This matters because ferritin may not fully reflect organ iron, and excess iron can silently injure the liver and other organs. [7]
6. Heart monitoring is needed in patients with long-standing iron overload. The purpose is to detect rhythm problems, heart weakness, or cardiomyopathy early. The mechanism is screening with clinical review and targeted cardiac testing when iron burden is high. This matters because untreated parenchymal iron overload can damage the heart. [8]
7. Endocrine monitoring helps detect diabetes, delayed puberty, thyroid problems, and other hormone complications related to iron toxicity. The purpose is to protect long-term quality of life. The mechanism is regular lab review and specialist referral when iron burden is high or symptoms suggest gland dysfunction. [9]
8. Bone health monitoring is useful because some people with CDA, especially CDA I, can develop low bone density or osteoporosis. The purpose is to prevent fractures and bone pain. The mechanism is bone density testing, nutrition support, physical activity guidance, and treatment when bone loss appears. [10]
9. Growth and development tracking in children is essential. The purpose is to identify whether chronic anemia or iron burden is affecting growth, puberty, learning, or daily activity. The mechanism is repeated height, weight, developmental, and school-function review over time. [11]
10. Screening for gallstones matters because chronic hemolysis and bilirubin overload can promote stone formation. The purpose is to find stones before they cause infection, pain, or blocked bile ducts. The mechanism is symptom review and ultrasound when needed. [12]
11. Spleen size monitoring is important because splenomegaly can worsen anemia and sometimes affect blood cell survival. The purpose is to track disease burden and decide whether further intervention is needed. The mechanism is physical examination and imaging when needed. [13]
12. Avoiding unnecessary iron supplements is a practical non-drug step. The purpose is to stop iron overload from becoming worse in a disease that may already absorb too much iron. The mechanism is reducing avoidable iron intake unless a doctor proves true iron deficiency, which is uncommon in classic CDA with overload. [14]
13. Vaccination and infection prevention are especially important if splenectomy is being considered or has already been done. The purpose is to lower the risk of severe infection. The mechanism is keeping routine vaccines up to date and following specialist guidance for post-splenectomy protection. [15]
14. Exercise adjusted to energy level can help stamina, mood, bone strength, and general health. The purpose is support, not cure. The mechanism is gentle conditioning without pushing through severe anemia symptoms. Overexertion is not useful when hemoglobin is very low. [16]
15. Nutrition counseling can help patients eat enough calories, protein, folate-rich foods, calcium, and vitamin D while avoiding self-prescribed iron products. The purpose is to support marrow function, growth, and bone health. The mechanism is reducing deficiency risk and supporting overall resilience during chronic illness. [17]
16. Pregnancy planning and high-risk obstetric care may be needed for affected women. The purpose is to manage anemia, transfusion needs, and iron-related risks safely. The mechanism is pre-pregnancy counseling and close monitoring during pregnancy. [18]
17. Psychosocial support helps children and adults cope with chronic fatigue, hospital visits, rare-disease stress, and school or work burden. The purpose is better quality of life. The mechanism is counseling, family education, and practical support. [19]
18. Family counseling and carrier testing may help relatives understand inheritance and future reproductive risk. The purpose is informed family planning. The mechanism is genetic counseling based on the confirmed mutation. [20]
19. Management of extramedullary hematopoiesis when present may involve transfusion intensification, surgery, or low-dose radiation in selected cases. The purpose is to reduce masses or pressure symptoms caused by blood-forming tissue outside the marrow. The mechanism is suppression or removal of abnormal compensatory blood formation. [21]
20. Hematopoietic stem cell transplantation evaluation is a non-drug but major treatment step for very severe, selected cases. The purpose is potential cure. The mechanism is replacing the abnormal marrow system with donor stem cells. It is reserved for carefully chosen patients because transplant has serious risks. [22]
Drug treatments
1. Interferon alfa or peginterferon alfa is the most famous subtype-specific medicine in CDA type I. Its purpose is to improve anemia and reduce ineffective erythropoiesis; long-term reports also describe reduced iron burden in responders. The mechanism is not completely understood, but it appears to improve abnormal erythroid maturation in CDA I. This is usually off-label use for CDA, not an FDA-labeled CDA indication. FDA-approved peginterferon alfa-2a labeling warns about serious neuropsychiatric, autoimmune, ischemic, and infectious adverse effects, so specialist supervision is essential. [23]
2. Deferasirox is an oral iron chelator used when transfusions or increased absorption cause iron overload. Its purpose is to lower body iron and protect the liver, heart, and endocrine organs. The mechanism is binding excess iron so it can be removed from the body. FDA labeling supports deferasirox for chronic transfusional iron overload; major risks include kidney injury, liver injury, and gastrointestinal bleeding, so monitoring is required. [24]
3. Deferoxamine is another iron chelator, usually given by infusion or injection. Its purpose is also removal of excess iron in patients with clinically important iron overload. The mechanism is iron binding and excretion. It is useful when oral chelation is not tolerated or not enough. FDA labeling identifies it as an iron-chelating agent and reminds clinicians about parenteral administration and safety monitoring. [25]
4. Deferiprone is an oral chelator that may be used in selected patients with iron overload, especially when other chelation approaches are inadequate. Its purpose is reduction of iron burden. The mechanism is chelation of ferric iron with urinary excretion. FDA labeling warns that deferiprone can cause agranulocytosis and neutropenia, so careful blood count monitoring is very important. [26]
5. Epoetin alfa is not a standard CDA drug, but in selected anemia settings some clinicians may consider an erythropoiesis-stimulating agent when there is a rational biologic reason and specialist support. Its purpose would be to stimulate red cell production. The mechanism is erythropoietin receptor activation. However, CDA is a disorder of ineffective erythropoiesis, so benefit is uncertain and it is not an established core treatment for typical CDA. FDA labeling also carries major safety warnings for erythropoiesis-stimulating agents. [27]
6. Folic acid is commonly used as supportive care in chronic hemolytic states and is recommended in reviews of CDA management to prevent deficiency. Its purpose is to support DNA synthesis in rapidly dividing marrow cells. The mechanism is replacement of folate needed for normal erythropoiesis. It is supportive care, not a cure, and dosing should follow a clinician’s advice. [28]
Dietary molecular supplements and nutrition support
1. Folic acid may help prevent folate depletion from chronic red cell turnover. 2. Vitamin B12 is used when low or borderline because deficiency can worsen anemia. 3. Vitamin D helps bone health, which matters because low bone density can occur in CDA I. 4. Calcium supports bone mineralization. 5. Protein-rich nutrition supports growth and marrow work. 6. Zinc may help general nutrition in deficiency states. 7. Omega-3 fats may support overall cardiovascular nutrition but do not treat CDA directly. 8. Multivitamin without iron may be useful in poor intake. 9. Magnesium can support general nutrition if low. 10. Energy-dense nutrition supplements can help underweight children with chronic illness. These are supportive only, and extra iron should be avoided unless iron deficiency is proven. [29]
Advanced or special medical therapies
There are no established FDA-approved “immunity booster” or regenerative drugs specifically for CDA. The most important advanced treatments are interferon alfa for selected CDA I, iron chelators for overload, transfusion programs for severe anemia, and hematopoietic stem cell transplantation for a small number of severe cases. Experimental directions such as registry-based research and future targeted therapy are still developing, so they should not be presented as standard proven care today. [30]
Surgeries or procedures
1. Splenectomy may be considered in selected patients, especially when splenomegaly contributes to symptoms or transfusion burden. 2. Cholecystectomy may be needed for symptomatic gallstones. 3. Bone marrow biopsy is a diagnostic procedure rather than a cure, but it may help in difficult cases. 4. Central venous access procedures may be needed in heavily transfused patients. 5. Hematopoietic stem cell transplantation is the major curative procedure for rare severe cases. These are used only when clearly indicated by the patient’s condition. [31]
Prevention points
You cannot fully prevent a genetic CDA after birth, but you can help prevent complications. Key steps are: avoid unnecessary iron, keep regular ferritin and MRI follow-up, attend hematology visits, treat iron overload early, screen for gallstones, watch the spleen, protect bone health, keep vaccines up to date, use genetic counseling for future pregnancies, and seek care early for worsening anemia or infection. [32]
When to see a doctor
See a doctor urgently for severe weakness, chest pain, fainting, breathing trouble, fast heartbeat, fever, yellowing that suddenly worsens, severe belly pain, dark urine, or signs of infection. See a hematologist for long-term care if there is chronic anemia, enlarged spleen, gallstones, delayed growth, repeated transfusions, or rising ferritin. Early specialist care is important because iron injury can grow silently over time. [33]
What to eat and what to avoid
Good choices include folate-rich foods such as leafy greens and beans, enough protein, dairy or other calcium sources, vitamin D support, fruits, vegetables, and balanced meals. Avoid iron supplements unless prescribed, avoid self-treatment with “blood builder” pills, limit alcohol if liver iron is high, and be careful with unproven supplements that claim to cure anemia. Food alone cannot cure CDA, but smart nutrition can support growth, bone health, and general strength. [34]
FAQs
Is CDA curable? Sometimes severe cases may be curable with stem cell transplantation, but many patients are managed long term with supportive care. Is CDA the same as iron deficiency anemia? No. Can CDA cause iron overload without many transfusions? Yes. Does every patient need transfusion? No. Can interferon help? Mostly selected CDA I patients. Is splenectomy routine? No, only selected cases. Are chelators important? Yes when iron overload appears. Can children grow normally? Many can, with good care. Is it inherited? Yes. Should family members get counseling? Often yes. Can gallstones happen? Yes. Can bones become weak? Yes, especially in CDA I. Should iron tablets be taken routinely? No, not unless deficiency is proven. Does every patient need transplant? No. Why is long-term follow-up essential? Because anemia severity and iron complications change over time. [35]
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: April 01, 2025.
